
About Dr. Kushal Gupta
- Dr. Kushal Gupta is a Medical Oncologist in Bengaluru, who specializes in treating solid tumors and hemato-lymphoid malignancies.
- He has 13 years of experience in the medical management of oncologic emergencies.
- He is also an expert in immunotherapy and targeted therapies in the treatment of advanced malignancies.
- He completed his MBBS from Vardhman Mahavir Medical College, New Delhi, in 2009.
- He has also done MD in General Medicine from PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, in 2013. After that, he pursued his DM in Medical Oncology from Tata Memorial Hospital, Mumbai, in 2017.
- He is an active member of the European Society of Medical Oncology, the Indian Society of Medical and Paediatric Oncologist, and the American Society of Clinical Oncology.
- He also established the first Medical Oncology Department at Homi Bhabha Cancer Hospital at Varanasi, Uttar Pradesh.
- He has published many research papers and articles on national and international fora.
OPD Schedule Of Dr. Kushal Gupta
Manipal hospitals Life's On, Jayanagar

MBBS, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi(2009)
MD, PGIMER and Dr. RML Hospital, New Delhi(2013)
DM, Tata Memorial Hospital, Mumbai(2017)
Consultant, Institute of Oncology at Narayana Health, MMI Hospital, Raipur, Chattisgarh
Registrar, Tata Memorial Centre(2018)
Senior Resident, BL Kapoor Hospital and Safdarjung Hospital, New Delhi
Consultant, Manipal hospitals Life's On, Jayanagar(2023)
Papers Published
-
Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
+ Read More- Show Less
-
Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
-
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
-
Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
-
Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
-
Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.
Send Your Enquiry
Fill in your details and our medical experts will contact you within 24 hours.
Want to consult the doctor?
Don't Ignore Your Health!
Other Top Medical Oncologist In Bangalore


Dr. Amit Rauthan


